120 related articles for article (PubMed ID: 33648834)
21. Quantitation of phenylbutyrate metabolites by UPLC-MS/MS demonstrates inverse correlation of phenylacetate:phenylacetylglutamine ratio with plasma glutamine levels.
Jiang Y; Almannai M; Sutton VR; Sun Q; Elsea SH
Mol Genet Metab; 2017 Nov; 122(3):39-45. PubMed ID: 28888854
[TBL] [Abstract][Full Text] [Related]
22. Phenylbutyrate exerts adverse effects on liver regeneration and amino acid concentrations in partially hepatectomized rats.
Holecek M; Vodenicarovova M
Int J Exp Pathol; 2016 Jun; 97(3):278-84. PubMed ID: 27381898
[TBL] [Abstract][Full Text] [Related]
23. Safety and efficacy of glycerol phenylbutyrate for management of urea cycle disorders in patients aged 2months to 2years.
Berry SA; Longo N; Diaz GA; McCandless SE; Smith WE; Harding CO; Zori R; Ficicioglu C; Lichter-Konecki U; Robinson B; Vockley J
Mol Genet Metab; 2017 Nov; 122(3):46-53. PubMed ID: 28916119
[TBL] [Abstract][Full Text] [Related]
24. Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
Mokhtarani M; Diaz GA; Rhead W; Berry SA; Lichter-Konecki U; Feigenbaum A; Schulze A; Longo N; Bartley J; Berquist W; Gallagher R; Smith W; McCandless SE; Harding C; Rockey DC; Vierling JM; Mantry P; Ghabril M; Brown RS; Dickinson K; Moors T; Norris C; Coakley D; Milikien DA; Nagamani SC; Lemons C; Lee B; Scharschmidt BF
Mol Genet Metab; 2013 Dec; 110(4):446-53. PubMed ID: 24144944
[TBL] [Abstract][Full Text] [Related]
25. Acute effects of phenylbutyrate on glutamine, branched-chain amino acid and protein metabolism in skeletal muscles of rats.
Holecek M; Vodenicarovova M; Siman P
Int J Exp Pathol; 2017 Jun; 98(3):127-133. PubMed ID: 28621016
[TBL] [Abstract][Full Text] [Related]
26. Transition to glycerol phenylbutyrate for the management of urea cycle disorders: clinical experiences.
Sacchini M; Procopio E; Pochiero F; Scaturro G; Daniotti M; Donati MA
Eur Rev Med Pharmacol Sci; 2023 Nov; 27(22):11131-11142. PubMed ID: 38039045
[TBL] [Abstract][Full Text] [Related]
27. Self-reported treatment-associated symptoms among patients with urea cycle disorders participating in glycerol phenylbutyrate clinical trials.
Nagamani SC; Diaz GA; Rhead W; Berry SA; Le Mons C; Lichter-Konecki U; Bartley J; Feigenbaum A; Schulze A; Longo N; Berquist W; Gallagher R; Bartholomew D; Harding CO; Korson MS; McCandless SE; Smith W; Vockley J; Kronn D; Zori R; Cederbaum S; Merritt JL; Wong D; Coakley DF; Scharschmidt BF; Dickinson K; Marino M; Lee BH; Mokhtarani M
Mol Genet Metab; 2015; 116(1-2):29-34. PubMed ID: 26296711
[TBL] [Abstract][Full Text] [Related]
28. Sodium phenylbutyrate coated granules (Pheburane). Defective urea synthesis: a welcome formulation.
Prescrire Int; 2015 Feb; 24(157):35-6. PubMed ID: 25802911
[TBL] [Abstract][Full Text] [Related]
29. New insights in nutritional management and amino acid supplementation in urea cycle disorders.
Scaglia F
Mol Genet Metab; 2010; 100 Suppl 1(Suppl 1):S72-6. PubMed ID: 20299258
[TBL] [Abstract][Full Text] [Related]
30. Diabetes and branched-chain amino acids: What is the link?
Bloomgarden Z
J Diabetes; 2018 May; 10(5):350-352. PubMed ID: 29369529
[TBL] [Abstract][Full Text] [Related]
31. Phase 2 study of sodium phenylbutyrate in ALS.
Cudkowicz ME; Andres PL; Macdonald SA; Bedlack RS; Choudry R; Brown RH; Zhang H; Schoenfeld DA; Shefner J; Matson S; Matson WR; Ferrante RJ;
Amyotroph Lateral Scler; 2009 Apr; 10(2):99-106. PubMed ID: 18688762
[TBL] [Abstract][Full Text] [Related]
32. Arginase induction by sodium phenylbutyrate in mouse tissues and human cell lines.
Kern RM; Yang Z; Kim PS; Grody WW; Iyer RK; Cederbaum SD
Mol Genet Metab; 2007 Jan; 90(1):37-41. PubMed ID: 16935537
[TBL] [Abstract][Full Text] [Related]
33. Pharmacology and safety of glycerol phenylbutyrate in healthy adults and adults with cirrhosis.
McGuire BM; Zupanets IA; Lowe ME; Xiao X; Syplyviy VA; Monteleone J; Gargosky S; Dickinson K; Martinez A; Mokhtarani M; Scharschmidt BF
Hepatology; 2010 Jun; 51(6):2077-85. PubMed ID: 20512995
[TBL] [Abstract][Full Text] [Related]
34. Effects of different meal compositions and fasted state on the oral bioavailability of etravirine.
Schöller-Gyüre M; Boffito M; Pozniak AL; Leemans R; Kakuda TN; Woodfall B; Vyncke V; Peeters M; Vandermeulen K; Hoetelmans RM
Pharmacotherapy; 2008 Oct; 28(10):1215-22. PubMed ID: 18823217
[TBL] [Abstract][Full Text] [Related]
35. Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adult subjects: two single-dose, open-label, randomized-sequence, crossover studies.
Williams DD; Peng B; Bailey CK; Wire MB; Deng Y; Park JW; Collins DA; Kapsi SG; Jenkins JM
Clin Ther; 2009 Apr; 31(4):764-76. PubMed ID: 19446149
[TBL] [Abstract][Full Text] [Related]
36. Glutamine and hyperammonemic crises in patients with urea cycle disorders.
Lee B; Diaz GA; Rhead W; Lichter-Konecki U; Feigenbaum A; Berry SA; Le Mons C; Bartley J; Longo N; Nagamani SC; Berquist W; Gallagher RC; Harding CO; McCandless SE; Smith W; Schulze A; Marino M; Rowell R; Coakley DF; Mokhtarani M; Scharschmidt BF
Mol Genet Metab; 2016 Jan; 117(1):27-32. PubMed ID: 26586473
[TBL] [Abstract][Full Text] [Related]
37. Long-term safety and efficacy of glycerol phenylbutyrate for the management of urea cycle disorder patients.
Diaz GA; Schulze A; Longo N; Rhead W; Feigenbaum A; Wong D; Merritt JL; Berquist W; Gallagher RC; Bartholomew D; McCandless SE; Smith WE; Harding CO; Zori R; Lichter-Konecki U; Vockley J; Canavan C; Vescio T; Holt RJ; Berry SA
Mol Genet Metab; 2019 Aug; 127(4):336-345. PubMed ID: 31326288
[TBL] [Abstract][Full Text] [Related]
38. Branched-chain amino acids and ammonia metabolism in liver disease: therapeutic implications.
Holecek M
Nutrition; 2013 Oct; 29(10):1186-91. PubMed ID: 23756281
[TBL] [Abstract][Full Text] [Related]
39. Monitoring the treatment of urea cycle disorders using phenylbutyrate metabolite analyses: Still many lessons to learn.
Glinton KE; Minard CG; Liu N; Sun Q; Elsea SH; Burrage LC; Nagamani SCS
Mol Genet Metab; 2023 Nov; 140(3):107699. PubMed ID: 37717413
[TBL] [Abstract][Full Text] [Related]
40. Decreased plasma l-arginine levels in organic acidurias (MMA and PA) and decreased plasma branched-chain amino acid levels in urea cycle disorders as a potential cause of growth retardation: Options for treatment.
Molema F; Gleich F; Burgard P; van der Ploeg AT; Summar ML; Chapman KA; Lund AM; Rizopoulos D; Kölker S; Williams M;
Mol Genet Metab; 2019 Apr; 126(4):397-405. PubMed ID: 30827756
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
